Letter to the Editor

Reply: Heart Failure With Preserved Ejection Fraction: Types 1 and 2?

Please note: Supported in part by U.S. National Institutes of Health grants R01AG18917, R01AG045551, R01HL107257, P30-AG21331, and U24-AG059624 to Dr. Kitzman and R15NR016826 to Dr. Haykowsky. Dr. Kitzman is a consultant for Bayer, CinRx, Novartis, Relypsa, Abbvie, GlaxoSmithKline, AstraZeneca, Merck Sharp & Dohme, St. Luke’s Medical Center, Duke Clinical Research Institute, and Corvia Medical; has received funding from Novartis, Bayer, and St. Luke’s Medical Center; and holds stock in Gilead Sciences. Dr. Upadhya has received funding from Corvia, Novartis, and Bayer. Dr. Brubaker is a consultant for Merck Sharp & Dohme; and has received funding from Boston Scientific and Corvia Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.